Homepage
Author:
Zhongshan Kangfang Biological Medicine Co., LTD
Posted Date:
May 26, 2026
Over 40 Studies Featuring Akeso’s Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab’s HARMONi-6 Overall Survival Data Selected for Plenary Session
Zhongshan Kangfang Biological Medicine Co., LTD
May 26, 2026
Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026
Zhongshan Kangfang Biological Medicine Co., LTD
May 15, 2026
Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline
Zhongshan Kangfang Biological Medicine Co., LTD
April 28, 2026
Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026
Zhongshan Kangfang Biological Medicine Co., LTD
April 20, 2026
Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026
Zhongshan Kangfang Biological Medicine Co., LTD
April 7, 2026
Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026
Zhongshan Kangfang Biological Medicine Co., LTD
March 31, 2026
Akeso Reports Full-Year 2025 Financial Results
Zhongshan Kangfang Biological Medicine Co., LTD
March 27, 2026
Akeso Advances “IO 2.0 + ADC 2.0” Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab
Zhongshan Kangfang Biological Medicine Co., LTD
March 24, 2026
Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance
Zhongshan Kangfang Biological Medicine Co., LTD
March 15, 2026
Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results
Zhongshan Kangfang Biological Medicine Co., LTD
March 4, 2026
1
2
Next
